Sept 8 (Reuters) - Beigene Ltd
* Beigene presents preliminary Phase 1/2 clinical data on PARP inhibitor BGB-290 in patients with advanced solid tumors at the European Society for Medical Oncology 2017 Congress
* Beigene Ltd - "BGB-290 continues to demonstrate promising anti-tumor activity in preliminary data from Phase 1/2 trial"
* Beigene Ltd - "BGB-290 was generally well tolerated, and all observed treatment-related adverse events were grade 3 or lower in severity"
* Beigene Ltd says four patients discontinued treatment of BGB-290 due to treatment-emergent adverse events Source text for Eikon: Further company coverage: